Format

Send to

Choose Destination
J Heart Lung Transplant. 2007 Dec;26(12):1340-4.

Fatal diffuse alveolar damage in two lung transplant patients treated with cetuximab.

Author information

1
Division of Pulmonary and Critical Care Medicine, University of California at San Francisco, San Francisco, California 94143-0111, USA. lorriana.leard@ucsf.edu

Abstract

Organ transplant recipients are at increased risk for aggressive cutaneous squamous cell carcinomas (cSCC) that recur and metastasize despite treatment with surgery, radiation, or both. Therapies targeting the epidermal growth factor receptor (EGFR) are being explored as treatments for metastatic cSCC. We describe our experience with two single-lung transplant patients who developed metastatic cSCC; failed surgical resection, radiation or chemoradiation therapy; and were ultimately treated with an EGFR inhibitor, cetuximab. Both patients died shortly after initiation of cetuximab due to diffuse alveolar damage, suggesting that EGFR inhibitors should be used with extreme caution in lung transplant recipients.

PMID:
18096489
DOI:
10.1016/j.healun.2007.09.019
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center